Billiontoone, Inc. (NASDAQ:BLLN) Receives $126.71 Consensus Price Target from Analysts

Billiontoone, Inc. (NASDAQ:BLLN) has been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $126.7143.

A number of research analysts recently commented on the company. Weiss Ratings raised Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 23rd. Wall Street Zen downgraded Billiontoone from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Guggenheim initiated coverage on Billiontoone in a research report on Monday, June 29th. They issued a “buy” rating and a $125.00 target price on the stock. BTIG Research reduced their target price on Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. cut their target price on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research note on Thursday, August 6th.

Insider Activity

In other news, insider Nancy Joann Johnson sold 10,582 shares of the company’s stock in a transaction dated Tuesday, June 9th. The shares were sold at an average price of $100.47, for a total transaction of $1,063,173.54. Following the completion of the transaction, the insider owned 21,900 shares in the company, valued at approximately $2,200,293. This represents a 32.58% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Oguzhan Atay sold 32,500 shares of the stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $136.95, for a total transaction of $4,450,875.00. Following the completion of the sale, the chief executive officer directly owned 20,000 shares in the company, valued at approximately $2,739,000. This trade represents a 61.90% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 213,466 shares of company stock valued at $24,557,044. Company insiders own 50.22% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Adams Street Partners LLC bought a new position in Billiontoone in the 4th quarter worth approximately $140,063,000. Baillie Gifford & Co. acquired a new position in Billiontoone during the 4th quarter worth $103,786,000. Price T Rowe Associates Inc. MD acquired a new position in Billiontoone during the 4th quarter worth $39,717,000. JPMorgan Chase & Co. bought a new position in shares of Billiontoone in the fourth quarter worth $32,078,000. Finally, Wasatch Advisors LP bought a new position in shares of Billiontoone in the first quarter worth $29,179,000.

Billiontoone Stock Down 0.8%

Shares of NASDAQ:BLLN opened at $93.33 on Friday. The company has a market capitalization of $4.40 billion and a price-to-earnings ratio of 133.33. The company has a 50 day moving average of $116.41 and a two-hundred day moving average of $94.59. Billiontoone has a 52-week low of $61.96 and a 52-week high of $150.44. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17.

Billiontoone (NASDAQ:BLLN) last posted its earnings results on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting analysts’ consensus estimates of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The business had revenue of $109.45 million for the quarter. As a group, analysts forecast that Billiontoone will post 0.83 earnings per share for the current fiscal year.

About Billiontoone

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.